Health Care·Biotechnology·$20.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.12 | N/A | -33.33% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.12 | N/A | -33.33% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current performance and emphasized the importance of strategic adjustments. They did not provide specific guidance for future quarters.
Management highlighted challenges in meeting earnings expectations.
They acknowledged the need for improved operational efficiency moving forward.
This earnings report indicates that Moderna is facing challenges, particularly reflected in their EPS miss. The lack of revenue data and guidance may lead to uncertainty among investors. The stock reaction is not available, but the overall sentiment appears cautious as management focuses on operational improvements.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ELBIT SYSTEMS LTD
May 16, 2011